Design and synthesis of novel arylpiperazine derivatives containing the imidazole core targeting 5-HT2A receptor and 5-HT transporter

Journal of Medicinal Chemistry

Volumn 54, Issue 18, 2011, Pages 6305-6318

  Seo, Hee Jeong ^a   Park, Eun Jung ^a   Kim, Min Ju ^a   Kang, Suk Youn ^a   Lee, Suk Ho ^a   Kim, Hyun Jung ^a   Lee, Ki Nam ^a   Jung, Myung Eun ^a   Lee, Minwoo ^a   Kim, Mi Soon ^a   Son, Eun Jung ^a   Park, Woo Kyu ^b   Kim, Jeongmin ^a   Lee, Jinhwa ^a  

^a Green Cross Company   (South Korea)

^b Korea Research Institute of Chemical Technology   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 ARYLPIPERAZINE; SEROTONIN 2A ANTAGONIST; SEROTONIN 2C ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG DESIGN; DRUG SYNTHESIS; FORCED SWIMMING TEST; IC 50; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; BINDING, COMPETITIVE; CHO CELLS; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; IMIDAZOLES; MALE; MICE; MOTOR ACTIVITY; PIPERAZINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 80052790873     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm200682b     Document Type: Article

References (41)

1. Murray, C. J.; Lopez, A. D. Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study Lancet 1997, 349, 1436-1442 (Pubitemid 27212192)
2. Olesen, J.; Saxena, P., Eds. 5-Hydroxyltryptamine Mechanisms in Primary Headaches, 1st ed.; Raven Press: New York, 1992.
3. Murray, C. J. L.; Lopez, A. D., Eds. The Global Burden of Disease; A Comprehensive Assessment of Mortality and Disability from Disease, Injuries and Risk Factors in 1990 and Projected to 2020. Vol. 1 of Global Burden of Disease and Injury Series; Harvard University Press: Cambridge, MA, 1996.
4. Mental Health: New Understanding, New Hope; Fact Sheet No. 265. The World Health Report 2001; World Health Organization: Geneva, 2001.
5. Blier, P.; Bergeron, R. The use of pindolol to potentiate antidepressant medication J. Clin. Psychiatry 1998, 59 (Suppl. 5) 16-25 (Pubitemid 28249103)
6. Katz, M. M.; Tekell, J. L.; Bowden, C. L.; Brannan, S.; Houston, J. P.; Berman, N.; Frazer, A. Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychophamacology 2004, 29, 566-579 and references therein. (Pubitemid 38365934)
7. Morphy, R.; Kay, C.; Rankovic, Z. From magic bullets to designed multiple ligands. Drug Discovery Today, 2004, 9, 641-651 and reference therein. (Pubitemid 38981718)
8. Pacher, P.; Kecskemeti, V. Trends in the development of new antidepressants. Is there a light at the end of the tunnel? Curr. Med. Chem. 2004, 11, 925-943 (Pubitemid 38425924)
9. Roberts, C.; Price, G. W.; Middlemiss, D. N. Ligands for the investigation of 5-HT autoreceptor function Brain Res. Bull. 2001, 56, 463-469 (Pubitemid 34031781)
10. T1 receptor augmentation strategies as enhanced efficacy therapeutics for psychiatric disorders Curr. Top. Med. Chem. 2008, 8, 1008-1023
11. T1A/B/D receptor antagonists leading to the discovery of 6-{2-[4-(2-methyl-5-quinolinyl) -1-piperazinyl]ethyl}- 4H -imidazo[5,1 -c ][1,4]benzoxazine-3-carboxamide (GSK088045) J. Med. Chem. 2010, 53, 5827-5843
12. 1A receptor ligands containing the pyrimido[2,1- f ]purine fragment: Synthesis, in vitro, and in vivo pharmacological evaluation J. Med. Chem. 2004, 47, 2659-2666 (Pubitemid 38580102)
13. Abou-Gharbia, M. A.; Yardley, J. P.; Childers, E. (American Home Products Co., USA) Aryl- and heteroaryl piperazinyl carboxamides having central nervous system activity. U.S. Patent 5,380,725, January 10, 1995.
14. Ballesteros, J.; Callado, L. F. Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomised controlled trials. J. Affective Disord. 2004, 79, 137-147 and reference therein. (Pubitemid 38340537)
15. 1A receptor antagonists in the dorsal raphe pathway: Role of somatodendritic autoreceptors J. Neurochem. 1997, 68, 2593-2603
16. Berman, R. M.; Anand, A.; Cappiello, A.; Miller, H. L.; Xu, X. S.; Oren, D. A.; Charney., D. S. The use of pindolol with fluoxetine in the treatment of major depression: Final results from a double-blind, placebo-controlled trial Biol. Psychiatry 1999, 45, 1170-1177 (Pubitemid 29236558)
17. 2A receptor antagonist: A comparison with the antidepressant, nefazodone Eur. J. Pharmacol. 2000, 407, 39-46
18. 2A receptor antagonistic activity Neuropharmacology 1997, 35, 1621-1626
19. Rush, A. J.; Armitage, R.; Gillin, J. C.; Yonkers, K. A.; Winokur, A.; Moldofsky, H.; Vogel, G. W.; Kaplita, S. B.; Fleming, J. B.; Montplaisir, J.; Erman, M. K.; Albala, B. J.; McQuade, R. D. Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder Biol. Psychiatry 1998, 44, 3-14 (Pubitemid 28305536)
20. Avila, A.; Vardona, X.; Martin-Baranera, M.; Maho, P.; Sastre, F.; Bello, J. Does nefazodone improve both depression and Parkinson disease? A pilot randomized trial J. Clin. Psychopharmacol. 2003, 23, 509-513 (Pubitemid 37128680)
21. Greene, D.; Barbhaiya, R. H. Clinical pharmacokinetics of nefazodone Clin. Pharmacokinet. 1997, 33, 260-275 (Pubitemid 27429893)
22. Kent, J. M. SNaRIs, NaSSAs, and NaRIs: New agents for the treatment of depression Lancet 2000, 355, 911-918 (Pubitemid 30137678)
23. Lawler, C. P.; Prioleau, C.; Lewis, M. M.; Mak, C.; Jian, D.; Schetz, J. A.; Gonzalez, A. M.; Sibley, D. R.; Mailman, R. B. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes Neuropsychopahrmacology 1999, 20, 612-627 (Pubitemid 29189265)
24. 3 partial agonist J. Pharmacol. Exp. Ther. 2005, 315, 1278-1287 (Pubitemid 41635416)
25. Oshiro, Y.; Sato, S.; Kurahashi, N. (Otsuka Pharmaceutical Co., Japan) Carbostyril derivatives. U.S. Patent 5,006,528, April 9, 1991.
26. 2c, and the serotonin transporter as a potential antidepressant Bioorg. Med. Chem. Lett. 2010, 20, 1705-1711
27. 2c, and the serotonin transporter as a potential antidepressant Bioorg. Med. Chem. 2010, 18, 6156-6169
28. 2c, and the serotonin transporter as a potential antidepressant Bioorg. Med. Chem. Lett. 2010, 20, 6439-6442
29. Lange, J. H. M.; Stuivenberg, H. H. V.; Vliet, B. J. V. (Solvay Pharmaceuticals) 1 H -imidazole derivatives as cannabinoid CB2 receptor modulators. U.S. Patent Application 2006/0194779, August 31, 2006.
30. Lange, J. H. M. Bioisosteric replacements of the pyrazole moiety of rimonabant: Synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists J. Med. Chem. 2005, 48, 1823-1838 (Pubitemid 40396315)
31. Kim, J. Y. Diarylimidazolyl oxadiazole and thiadiazole derivatives as cannabinoid CB1 receptor antagonists Bioorg. Med. Chem. Lett. 2009, 19, 142-145
32. Smith, R. A.; O'Connor, S. J.; Wirtz, S.-N.; Wong, W. C.; Choi, S.; Kluender, H. C. E.; Su, N.; Wang, G.; Achebe, F.; Ying, S. (Bayer Pharmaceuticals Co.) Imidazole-4-carboxamide derivatives, preparation and use thereof for treatment of obesity. WO 03/040107, May 15, 2003.
33. Buettelmann, B.; Ceccarelli, S. M.; Jaeschke, G.; Kolczewski, S.; Porter, R. H. P.; Vieira, E. (F. Hoffmann-La Roche AG) Imidazole derivatives III. WO 2005/003117, January 13, 2005.
34. 3 receptor subtype J. Med. Chem. 2001, 44, 3175-3186 (Pubitemid 32862348)
35. 1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia Pharmacol., Biochem. Behav. 2005, 82, 361-372 (Pubitemid 41727948)
36. + channels J. Pharmacol. Sci. 2004, 95, 311-319 (Pubitemid 39037891)
37. Ostroff, R. B.; Nelson, J. C. Risperidone augmentation of selective serotonin reuptake inhibitors in major depression J. Clin. Psychiatry 1999, 60, 256-259 (Pubitemid 29193925)
38. Shelton, R. C.; Tollefson, G. D.; Tohen, M.; Stahl, S.; Gannon, K. S.; Jacobs, T. G.; Buras, W. R.; Bymaster, F. P.; Zhang, W.; Spencer, K. A.; Feldman, P. D.; Meltzer, H. Y. A novel augmentation strategy for treating resistant major depression Am. J. Psychiatry. 2001, 158, 131-134 (Pubitemid 32047260)
39. Carpenter, L. L.; Yasmin, S.; Price, L. H. A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine Biol. Psychiatry 2002, 51, 183-188 (Pubitemid 34127908)
40. 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders Neuropsychopharmacology 2003, 28, 402-412
41. Porsolt, R. D.; Bertin, A.; Jalfre, M. "Behavioural despair" in rats and mice: Strain differences and the effects of imipramine Eur. J. Pharmacol. 1978, 51, 291-294 (Pubitemid 9208063)